Ho P.-H.TSEN-FANG TSAI2020-10-222020-10-2220170385-2407https://www.scopus.com/inward/record.uri?eid=2-s2.0-85019606710&doi=10.1111%2f1346-8138.13909&partnerID=40&md5=807fe9de034fd0b0c4f1a8d6adfe08b2https://scholars.lib.ntu.edu.tw/handle/123456789/517575[SDGs]SDG3autoantibody; basement membrane antibody; BP180 antibody; clobetasol propionate; etretin; immunoglobulin; immunoglobulin C3; immunoglobulin G; methotrexate; secukinumab; topical agent; unclassified drug; ustekinumab; clobetasol; glucocorticoid; monoclonal antibody; secukinumab; adverse outcome; aged; antibody titer; blister; bullous pemphigoid; case report; clinical article; disease duration; drug efficacy; drug response; drug treatment failure; drug withdrawal; enzyme linked immunosorbent assay; eosinophilia; female; histopathology; human; immunofluorescence test; Letter; phototherapy; psoriasis; bullous pemphigoid; chemically induced; psoriasis; Aged; Antibodies, Monoclonal; Clobetasol; Enzyme-Linked Immunosorbent Assay; Female; Glucocorticoids; Humans; Pemphigoid, Bullous; Psoriasisletter10.1111/1346-8138.13909285439602-s2.0-85019606710